Indiana University School of Medicine researchers received over $243 million in total funding from the National Institutes of Health during federal fiscal year 2023 — a more than $54 million increase over the past five years, or 28%.
Indiana University School of Medicine researchers have uncovered vital insights regarding a liver trigger that blocks an undesired immune response from gene therapy, surprisingly resulting in the activation of specific immune cells, despite the liver's typical role in suppressing immune responses. The findings, published in Molecular Therapy, may pave the way for change in immunomodulation strategies for desired and long-lasting effects of gene therapy.
A recent study led by Indiana University School of Medicine in collaboration with the University of Chicago Medicine presents exciting future possibilities for the management of type 1 diabetes and the potential reduction of insulin dependency.
Results from a new study of diabetic foot ulcers and the risk of wound recurrence can help health care workers measure the likelihood that the wound will reopen in the future. These findings are likely to lead to further studies aimed at decreasing amputation rates for the tens of millions of people with diabetes in the United States.
A clinical study conducted by Indiana University School of Medicine researchers revealed that oral verapamil, a readily available and commonly used drug to treat high blood pressure and heart conditions, can also improve the pancreas’ insulin secretion in children with newly-diagnosed type 1 diabetes (T1D).
Researchers at Indiana University School of Medicine are celebrating Federal Drug Administration approval of teplizumab, a new immunotherapy drug that delays the onset of type 1 diabetes in at-risk individuals by an average of almost three years.
Researchers are investigating novel regenerative medicine approaches to better manage vascular health complications from type 2 diabetes that could someday support blood vessel repair in the eye among diabetic patients with early retinal vascular dysfunction.
For people with diabetes who are insulin dependent, glycemic control is a full-time job. But what if their medication could do the work for them—an insulin whose activity in the bloodstream responds to the blood glucose levels and adjusts accordingly?
A group of leading scientists is holding a mirror to the diabetes research community and calling for the improved support of its female constituents. Linda DiMeglio, MD, MPH, of Indiana University School of Medicine and Mark Atkinson, PhD, of the University of Florida, led a deep dive into the historical representation of women in the diabetes research community and that of women in influential positions among four major diabetes organizations.